Downregulation of HHLA2 inhibits ovarian cancer progression via the NF-κB signaling pathway and suppresses the expression of CA9
-
Published:2023-07
Issue:
Volume:388-389
Page:104730
-
ISSN:0008-8749
-
Container-title:Cellular Immunology
-
language:en
-
Short-container-title:Cellular Immunology
Author:
Fu Yuanyuan, Zheng Panpan, Zheng Xiao, Chen Lujun, Kong Caixia, Liu Wenzhi, Li Shuping, Jiang JingtingORCID
Reference44 articles.
1. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations;Letai;Cancer Cell,2022 2. Lin Ding, Qian Yu, Shuo Yang, Wen-Jing Yang, Te Liu, Jing-Rong Xian, Tong-Tong Tian, Tong Li, Wei Chen, Bei-Li Wang, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. Front. Immunol., 2022, 13, 831101. 3. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target;Wei;Sci. Immunol.,2021 4. Rupal S. Bhatt, Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman, Chun-Hau Chen, Opeyemi A. Jegede, Paul J. Catalano, Jean-Christophe Pignon, Maura Sticco-Ivins, Baogong Zhu, Ping Hua, Jo Soden, Jie Zhu, David F. Mcdermott, Antonio R. Arulanandam, Sabina Signoretti, Gordon J. Freeman. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol. Res., 2021, 9 (2):156-169. 5. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival;Yan;Cancer Lett.,2019
|
|